Core Points - The company held a successful online performance briefing for Q3 2025, with a high response rate to investor questions [1] - The company is focusing on external expansion strategies and optimizing collaboration with stakeholders to drive growth in high-potential areas [2][3] - The company reported stable growth in its Russian subsidiary, indicating positive future prospects for its business in Russia [2] - The company experienced year-on-year growth in overseas sales, particularly in the Asia-Pacific, Middle East, and India regions [3] - The management team has been adjusted to include individuals with industry operational backgrounds, aiming to enhance business focus and strategic direction [8][14] Business Performance - Domestic business revenue proportion was inquired but not disclosed in the responses [2] - The company acknowledged challenges in the domestic market, including price competition and reduced reagent consumption, impacting revenue [10] - The company is committed to improving communication with institutional investors and addressing their concerns [6][13] Strategic Direction - The company is positioned as the only medical device platform under the China Resources Group, focusing on digitalization and intelligence in the medical industry [21][15] - The management emphasized the importance of integrating internal and external resources to enhance operational efficiency and sustainable development [20][14] - The company is exploring mergers and acquisitions to strengthen its asset base and market position [10][2]

Core Viewpoint - The company, Di Rui Medical (300396.SZ), clarifies that its products do not involve innovative drugs and focuses on the research, production, marketing, and service of medical testing instruments and related test strips and reagents [1] Group 1 - The company's main business is centered around medical testing instruments and supporting test strips and reagents [1] - The products are utilized for routine health check-ups and auxiliary diagnosis of diseases [1] - The testing of bodily fluids such as urine and blood provides reference information for disease prevention and treatment [1]

Core Viewpoint - The company has received a patent for a chemical luminescent immunoassay kit related to Alzheimer's disease, indicating progress in its product development [1]. Group 1 - The company has been asked by investors about the timeline for the market launch of its AD detection products [1]. - The company advises investors to monitor its official website and regular reports for updates on product sales and market launch information [1]. - The company has obtained an invention patent for the chemical luminescent immunoassay kit and its preparation method related to Alzheimer's disease [1].

Core Viewpoint - Dierui Medical, a leading manufacturer of medical testing instruments and reagents in China, is facing challenges in revenue and profitability, with a significant decline in domestic sales while experiencing growth in overseas markets [2][5][6]. Group 1: Company Overview - Dierui Medical was established on December 26, 1994, and listed on the Shenzhen Stock Exchange on September 10, 2014. The company is headquartered in Changchun, Jilin Province [1]. - The main business of Dierui Medical includes the research, production, and sales of medical testing instruments and supporting reagents, categorized under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [1]. Group 2: Financial Performance - For Q3 2025, Dierui Medical reported revenue of 469 million yuan, ranking 19th among 39 companies in the industry. The industry leader, New Industries, achieved revenue of 3.428 billion yuan, while the industry average was 708 million yuan [2]. - The net profit for the same period was -87.25 million yuan, placing the company 32nd in the industry. The top performer, Ji'an Medical, reported a net profit of 1.588 billion yuan, with the industry average at 110 million yuan [2]. Group 3: Financial Ratios - As of Q3 2025, Dierui Medical's debt-to-asset ratio was 31.92%, slightly up from 31.73% year-on-year, which is higher than the industry average of 18.29% [3]. - The gross profit margin for Q3 2025 was 33.41%, down from 43.41% in the previous year, and below the industry average of 56.20% [3]. Group 4: Management Team - The chairman, Guo Ting, has extensive experience in the industry, having held various senior positions in pharmaceutical companies. The general manager, Lang Tao, also has a strong background in the pharmaceutical sector [4]. Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.48% to 16,800, while the average number of shares held per shareholder increased by 6.92% to 16,200 shares [5]. - The company has seen a decline in domestic sales, with reagent revenue down 22.75% and instrument revenue down 75.97%. However, overseas market revenue increased by 24.02% [5]. Group 6: Market Outlook - The company is adjusting its revenue forecasts for 2025-2026 to 679 million yuan and 720 million yuan, respectively, with a projected net profit of -28 million yuan and 53 million yuan for the same years [5]. - The company is focusing on optimizing its sales structure and expanding its overseas market presence, particularly in Southeast Asia and Belt and Road Initiative countries [6].

Core Insights - The company reported a significant decline in revenue and net profit for Q3 2025, with total revenue at 469 million yuan, down 60.12% year-on-year, and a net loss of 87.25 million yuan, a decrease of 145.31% compared to the same period last year [1][3]. Financial Performance - Total revenue for the company was 469 million yuan, a decrease of 707 million yuan from the same period last year, reflecting a year-on-year decline of 60.12% [1]. - The net profit attributable to shareholders was -87.25 million yuan, down 280 million yuan from the previous year, marking a year-on-year decline of 145.31% [1]. - The net cash inflow from operating activities was -58.21 million yuan, an increase of 241 million yuan compared to the same period last year [1]. Key Financial Ratios - The latest debt-to-asset ratio is 31.92%, a decrease of 2.01 percentage points from the previous quarter, but an increase of 0.19 percentage points compared to the same period last year [3]. - The latest gross profit margin is 33.41%, down 5.45 percentage points from the previous quarter and down 10.00 percentage points year-on-year [3]. - The return on equity (ROE) is -4.60%, a decrease of 13.79 percentage points compared to the same period last year [3]. Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.32 yuan, a decrease of 1.03 yuan from the same period last year, reflecting a year-on-year decline of 145.31% [3]. - The total asset turnover ratio is 0.16 times, down 0.21 times from the same period last year, representing a year-on-year decline of 56.74% [3]. - The inventory turnover ratio is 0.58 times, down 0.67 times compared to the same period last year, indicating a year-on-year decline of 53.49% [3]. Shareholder Structure - The number of shareholders is 16,800, with the top ten shareholders holding a total of 149 million shares, accounting for 54.81% of the total share capital [3]. - The largest shareholder is Shenzhen Huade Xinrun Equity Investment Enterprise (Limited Partnership) with 28.3 million shares [3].

Core Viewpoint - The financial performance of Di Rui Medical has significantly declined in the first three quarters of 2025, with a revenue drop of 60.12% and a net profit loss of 87.25 million yuan, reflecting challenges in the domestic market and the impact of industry competition and pricing policies [1][2]. Financial Performance - The company's revenue for the first three quarters was 469 million yuan, a decrease of 60.12% year-on-year [1]. - The net profit attributable to shareholders was -87.25 million yuan, representing a year-on-year decline of 145.31% [1]. Strategic Adjustments - Di Rui Medical is focusing on risk mitigation, stability, and industrial development, which includes optimizing the board structure and adjusting the management team to include individuals with operational backgrounds [1]. - The company has clarified its R&D direction and areas of focus, aiming to fulfill the digitalization and intelligence responsibilities of the China Resources medical industry [1]. Market Expansion - The company is pursuing a dual-driven strategy for domestic and international markets, emphasizing localized management and product upgrades [1]. - Di Rui Medical has achieved some success in international markets, with several high-speed models registered in various countries, including India, the Philippines, and Turkey, showing year-on-year growth [1]. Domestic Market Challenges - The domestic market is under pressure due to competition and centralized procurement policies affecting reagent prices, prompting the company to adjust pricing policies and optimize performance assessments [2]. - The company plans to conduct a "100-day offensive" campaign in the fourth quarter to enhance performance and overcome challenges [2]. Shareholder Developments - The controlling shareholder, Huade Xinrun, has released a pledge on 45.6 million shares, which accounts for 59% of its holdings and 16.72% of the company's total share capital, resulting in no pledged shares remaining [2].

Group 1: AI and Health Innovation - The rapid development of AI technology is driving transformation in the healthcare sector, with a focus on proactive health management through a new model combining offline infrared detection and online AI health records [1] - The launch of the world's first health forecasting AI digital asset marks a significant step in establishing a credible health service path that integrates health screening, clinical diagnosis, and management [1] - The innovative model addresses the information gap between health screening and clinical diagnosis, creating a comprehensive health service pathway from warning to management [1] Group 2: Company Performance and Strategy - In the first three quarters of 2025, the company reported a revenue of 469 million yuan, a decrease of 60.12% year-on-year, and a net profit attributable to shareholders of -87.25 million yuan, down 145.31% [3] - The company's performance is under pressure primarily due to the domestic market, influenced by competition and price adjustments in the in vitro diagnostic industry [3] - The company is implementing a "100-day offensive" initiative in the fourth quarter to enhance performance and overcome challenges [3] Group 3: Technological Advancements - The company has developed an intelligent recognition system for urine analysis, utilizing AI and deep learning to improve diagnostic capabilities [2] - The system employs a multi-layer convolutional neural network (CNN) architecture trained on a large dataset of clinical urine samples, enhancing the identification of various pathological components [2] - Innovative techniques such as transfer learning and data augmentation have been introduced to address challenges in medical imaging, improving the model's ability to recognize low-frequency pathological features [2]

迪瑞医疗科技股份有限公司（以下简称"公司"）《2025 年第三季度报告》 于 2025 年 10 月 28 日在中国证监会指定的创业板信息披露网站上披露。为便于 投资者进一步了解公司的生产经营等情况，公司拟定于 2025 年 10 月 28 日（星 期二）15：00 至 16：30 采取网络远程的方式举办 2025 年第三季度报告网上业 绩说明会。 投资者参与本次业绩说明会具体方式如下： 1、时间：2025 年 10 月 28 日（星期二）15：00 至 16：30； 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-051 2、参与方式：投资者可登录全景网"投资者关系互动平台"（https://ir.p5w.net） 参与本次业绩说明会。 迪瑞医疗科技股份有限公司 出席本次网上业绩说明会的人员有：公司副总经理、财务总监张兴艳女士， 董事、副总经理、董事会秘书安国柱先生（如有特殊情况，参与人员会有调整）。 关于举行 2025 年第三季度报告网上业绩说明会的公告 欢迎广大投资者积极参与。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司《2025 年第三季度报告》于 2025 年 10 月 28 日 在中国证监会指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上 披露，敬请投资者注意查阅。 特此公告。 迪瑞医疗科技股份有限公司董事会 2025 年 10 月 27 日 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-050 迪瑞医疗科技股份有限公司 2025 年第三季度报告披露提示性公告 ...

Financial Performance - Revenue for Q3 2025 was CNY 118,056,019.80, a decrease of 60.27% compared to the same period last year[5] - Net profit attributable to shareholders was CNY -58,941,976.28, a decline of 315.63% year-on-year[5] - The company reported a basic and diluted earnings per share of CNY -0.2161, down 315.67% from the previous year[5] - Total operating revenue for the current period was ¥468,750,514.30, a significant decrease from ¥1,175,445,053.92 in the previous period, representing a decline of approximately 60%[35] - Operating profit for the current period was a loss of ¥93,467,863.32, compared to a profit of ¥214,106,161.38 in the previous period[36] - Net profit for the current period was a loss of ¥87,253,663.92, contrasting with a net profit of ¥192,566,604.72 in the previous period[36] - The total comprehensive income for the period attributable to the parent company was -82,064,717.11 yuan, compared to 193,444,937.30 yuan in the previous period[37] - The basic and diluted earnings per share for the current period were both -0.3200 yuan, down from 0.7062 yuan in the previous period[37] Cash Flow - Cash flow from operating activities showed a net outflow of CNY -58,210,987.00, an increase of 80.56% in outflow compared to the previous year[5] - The net cash flow from operating activities increased by CNY 241.16 million, a growth of 80.56%, mainly due to reduced procurement payments and controlled operating expenses[24] - Cash inflows from operating activities totaled 708,497,319.40 yuan, a decrease of 22.2% from 911,446,107.42 yuan in the previous period[38] - Cash outflows from operating activities amounted to 766,708,306.40 yuan, down from 1,210,818,059.95 yuan in the previous period[39] - The net cash flow from operating activities was -58,210,987.00 yuan, an improvement from -299,371,952.53 yuan in the previous period[39] - The net cash flow from investing activities decreased by CNY 272.69 million, a decline of 3627.79%, primarily due to increased cash payments for purchasing structured deposits[24] - The net cash flow from investing activities was -265,176,908.77 yuan, compared to a positive cash flow of 7,516,792.34 yuan in the previous period[39] - The net cash flow from financing activities increased by CNY 58.83 million, a growth of 64.45%, mainly due to a decrease in dividend payments compared to the previous year[24] - Cash inflows from financing activities were 425,000,000.00 yuan, significantly higher than 115,000,000.00 yuan in the previous period[39] - The net cash flow from financing activities was -32,445,646.99 yuan, an improvement from -91,270,818.77 yuan in the previous period[39] Assets and Liabilities - Total assets decreased by 10.38% to CNY 2,784,841,089.87 compared to the end of the previous year[5] - Total assets decreased to ¥2,784,841,089.87 from ¥3,107,533,388.27, reflecting a decline of approximately 10.4%[33] - Total liabilities decreased to ¥889,037,469.80 from ¥1,058,764,060.35, showing a reduction of about 16%[33] - Current liabilities totaled ¥478,180,089.99, down from ¥697,309,012.71, indicating a decrease of approximately 31.4%[33] - Non-current assets decreased to ¥1,074,164,186.50 from ¥1,263,422,546.45, representing a decline of about 15%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,848[27] - The largest shareholder, Shenzhen Huadexin Run Equity Investment Enterprise, holds 28.34% of shares, amounting to 77,288,400 shares, with 45,600,156 shares pledged[28] Operational Adjustments - The company adjusted pricing policies for key models in response to market competition, impacting short-term sales and profits[8] - The company experienced a 60.12% decrease in operating income due to market environment impacts and business model adjustments[20] - The company aims to conduct a "100-day campaign" in Q4 to improve performance and address challenges[8] - The company reported a significant increase in cash flow from operations, indicating improved operational efficiency and cost control measures[24] Other Financial Metrics - Financial expenses decreased by 610.54% due to increased interest income from maturing structured deposits[21] - Research and development expenses were ¥74,028,362.03, down from ¥95,643,187.59, indicating a reduction of approximately 22.6%[36] - Other comprehensive income after tax for the current period was ¥5,189,997.93, compared to ¥867,601.54 in the previous period, showing a significant increase[36] - The total amount of cash and cash equivalents at the end of the reporting period was CNY 235.01 million, down from CNY 586.68 million at the beginning of the period[31] - The accounts receivable decreased from CNY 441.69 million at the beginning of the period to CNY 335.81 million at the end of the period[31] - The company had a total of 436,936 restricted shares at the end of the reporting period, with 16,382 shares released from restrictions during the period[29] Audit Status - The company’s third-quarter financial report was not audited[41]